The comparison of efficacy between losartan and diltiazem as antiproteinuric agent in non-diabetic renal diseases | [Journal of Ayub Medical College • 2021]

Author(s):

1. Salahuddin: Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan

2. Malik Nadeem Azam: Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan

3. Khalid Mehmood Raja: Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan

4. Abdur Rehman Arshad: Department of Nephrology, CMH, Peshawar, Pakistan

5. Faryal Riaz Khan: Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan

6. Abdul Wahab Mir: Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan

7. Taleah Tahir: Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan

8. Batool Butt: Department of Nephrology, Fauji Foundation Hospital, Rawalpindi, Pakistan

9. Wahaj: Department of Nephrology, Abbottabad International Medical College, Abbottabad, Pakistan

10. Anum Khan: Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan

Abstract:

Background: Multiple options have been tried to counter the proteinuria secondary to renal diseases. Clinicians and researchers are trying to find the best option for this purpose. Objective: To compare efficacy of Losartan and Diltiazem in management of proteinuria in nondiabetic renal diseases at a tertiary care hospital of Pakistan. It was a Quasi-experimental study, conducted at the Department of nephrology Pak Emirates Military Hospital Rawalpindi. Five months, November 2020 to March 2021. Methods: A total of 122 patients of non-diabetic renal diseases with significant proteinuria were included in the study. They were randomly divided into two groups via lottery method. Group I received losartan while group II received Diltiazem in standard dose for three months. After three months they underwent 24 hours' urinary protein levels and divided into complete, partial and non-responders to treatment. Age, gender, duration of illness and type of antiproteinuric treatment was correlated with response to treatment among the study population. Results: Out of 122 patients, 80 (65.6%) were males while 42 (34.4%) were females. Membranous nephropathy 20 (16.4%) was the commonest non-diabetic renal disease seen in our study participants. Thirty (24.5%) had complete remission after three months of treatment, 60 (49.2%) had partial response while 32 (26.3%) had no response to treatment. Chisquare test revealed that use of losartan had statistically significant relationship (p-value<0.001) with good response among the study participants. Conclusion: Membranous nephropathy leading to proteinuria was the commonest non-diabetic renal disease encountered in our setup. Around 2/3rd of our patients showed either complete or partial response to treatment and Losartan was superior to Diltiazem in achieving response in our study participants.

Page(s): 492-495

DOI: DOI not available

Published: Journal: Journal of Ayub Medical College, Volume: 33, Issue: 3, Year: 2021

Keywords:

Proteinuria , Losartan , Diltiazem , Nondiabetic renal disease

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views